|
Chronologic order | Vector | Gene | Host | Rout of administration | Results and reference |
|
1990 | Vaccina virus | gD | Rabbits | Intradermal injection | No effect on herpes simplex keratitis during 16 days postinfection [99] |
|
1997 | Plasmid DNA | IL-10, IL-2, GM-CSF | Mice | Topical or intramuscular | Topical: IL-10, only, reduced lesion severity. Intramuscular: no effect [100] |
|
1998 | Plasmid DNA | IL-2, IL-4, IL-10, IFN-γ | Mice | Topical | IL-4 or IL-10: reduced lesion severity 25 days post-infection; IL-2 or IFN-γ: no effect [101] |
Plasmid DNA | IL-2, IL-4, IL-10 | Mice | Topical, nasal, or intramuscular | Topical administration of IL-4 or IL-10 lowered lesion severity 21 days after infection [102] |
|
1999 | Plasmid DNA | IFN-α1 | Mice | Topical | Increased survival if treated 1 day pre-infection [69] |
|
2000 | Plasmid DNA | gB1 | Rabbits | Subconjunctival or intramuscular injection | Complete survival and reduction of lesions following intramuscular administration only [103] |
Plasmid DNA | gD, gD-IL-2 | Mice | Subconjunctival injection | Good survival for grafts and prevention of stromal, but not epithelial, keratitis [104] |
Plasmid DNA | IFN-α1 | Mice | Topical, nasal, or vaginal administration | Topical application improved the survival when treated 1 day before infection [105] |
Plasmid DNA | IFN-β | Mice | Topical | Increased survival only when applied 1 day before infection [106] |
Plasmid DNA | IFN-α1 | Mice | Topical | Increased survival only when applied 12 hours before infection [107] |
|
2001 | Plasmid DNA | IFN-α1 | Mice | Topical | Increased survival [108] |
Plasmid DNA | gB | Mice | Mucosal | Increased INF-γ [109] |
|
2002 | Plasmid DNA | gD-IL-2 | Mice | Subconjunctival injection | Complete prevention of stromal, but not epithelial, keratitis 10 days after infection [110] |
Plasmid DNA | gD-IL-2 | Mice | Topical conjunctival | Complete prevention of stromal, but not epithelial, keratitis [111, 112] |
Plasmid DNA | IL-12, IP-10 | Mice | Topical | Suppression of lesions using both transgenes. IP-10, but not IL-12, suppressed lesions [113] |
|
2003 | Antisense oligonucleotides | TNF-α | Mice | Subepithelial injection | Reduction of herpes simplex keratitis signs 14 days after infection [114] |
HSV-1 | IL-2, IL-4, IFN-γ | Mice | Intraperitoneal injection | All transgenes: complete survival and prevention of corneal scarring 28 days after infection [115] |
|
2004 | Plasmid DNA | gB, gC, gD, gE and gI | Mice | Intramuscular injection | Complete survival and prevention of corneal scarring 28 days after infection [116] |
siRNA duplexes with or without TargeTran | VEGF | Mice | Subconjunctival or intravenous injection | Subconjunctival or systemic administrations suppressed lesions 10 days after infection [117] |
|
2005 | HSV-1 | IL-12p35, IL-12p40 | Mice | Intraperitoneal injection | Both transgenes: complete survival and prevention of corneal scarring 28 days after infection [118] |
Plasmid DNA | IL-18 | Mice | Topical | Suppression of lesions 12–21 days post-infection [70] |
Plasmid DNA encoding shRNA | Matrix metalloproteinase-9 | Mice | Intrastromal injection | Suppression of lesions during 21 days after infection [119] |
|
2008 | siRNA | TNF-α | Mice | Intraperitoneally | Inhibition of TNF-α [120] |
Plasmid DNA | IL-10 | Mice | Topical | Modulate the inflammation severity [121] |
|
2009 | Plasmid DNA | VEGFR2 VEGFR3 | Mice | Subconjunctival injection | Control vascularisation after HSV-1 infection [72] |
|
2010 | Nanoparticles | IL-21 and gD vaccine | Mice | Ocular mucosal administration | Inhibits ocular HSV-1 [122] |
DNA plasmid | B and T lymphocyte attenuator | Mice | Intraperitoneal injection | Decreased CD4+ T mediated cell response [123] |
|